SURGICLOT
Pre-commercial- Indications
- Surgical bleeding, Orthopedic surgery, Spine surgery
Company intelligence / Profile preview
St. Teresa Medical develops proprietary hemostatic medical devices using nanotechnology platforms such as FibriSEAL, FASTCLOT®, and SurgiClot to control surgical and traumatic bleeding by accelerating the clotting cascade with embedded human-derived clotting proteins. The company’s products are designed for rapid, robust clot formation in surgery or trauma settings but do not appear to be commercially launched yet. No published pivotal clinical trial results were found.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on St. Teresa Medical.